The effect of monoallelic variants in the ALPL gene on the natural course of hypophosphatasia in Russia

Trial Identifier:	D8400R00003
Sponsor:	AstraZeneca
Start Date:	December 2025
Primary Completion Date:	June 2027
Study Completion Date:	June 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Russian Federation	Moscow, Russian Federation
Russian Federation	Saint Petersburg, Russian Federation

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.